Unlike $BLU, which we both made money on last week, this company has more than one product in the works. Look up their GEN-1 treatment still undergoing clinical testing for multiple cancer types. This company isn't 'dead' because of the negative news the other day. Worth less? Sure. But way oversold at these levels. Again, more than one treatment. Other still holds promise. Google it and look it up on their site and read the information.
Either way, we'll see at this time tomorrow.
News 
Market Data 
Discover 
